Technical Analysis for IKNA - Ikena Oncology, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 17.99 | -2.49% | -0.46 |
IKNA closed down 2.49 percent on Friday, April 16, 2021, on 13 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | N/A | Down |
| Historical IKNA trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Hot IPO Pullback | Bullish Swing Setup | 0.00% | |
| Calm After Storm | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Calm After Storm | Range Contraction | -2.49% | |
| Narrow Range Bar | Range Contraction | -2.49% | |
| Outside Day | Range Expansion | -2.49% | |
| NR7 | Range Contraction | 1.75% | |
| Hot IPO Pullback | Bullish Swing Setup | 0.56% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakdown | 1 day ago |
| Down 5% | 1 day ago |
| Down 3% | 1 day ago |
| Down 2 % | 1 day ago |
| Down 1% | 1 day ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: ???
Ikena Oncology, Inc., a targeted oncology company, focuses on developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, a selective AHR antagonist; IK-412, a recombinant human kynurenine-degrading enzyme; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Biology Oncology Colorectal Cancer Cancer Therapies Signal Transduction Novel Cancer Transcription Factors
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Biology Oncology Colorectal Cancer Cancer Therapies Signal Transduction Novel Cancer Transcription Factors
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 37.61 |
| 52 Week Low | 14.16 |
| Average Volume | 436,671 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 0.00 |
| 20-Day Moving Average | 0.00 |
| 10-Day Moving Average | 19.04 |
| Average True Range | 5.33 |
| ADX | 0.0 |
| +DI | 10.83 |
| -DI | 12.37 |
| Chandelier Exit (Long, 3 ATRs ) | 21.63 |
| Chandelier Exit (Short, 3 ATRs ) | 30.14 |
| Upper Bollinger Band | 0.00 |
| Lower Bollinger Band | 0.00 |
| Percent B (%b) | 0.0 |
| BandWidth | 0.00 |
| MACD Line | -1.20 |
| MACD Signal Line | -0.53 |
| MACD Histogram | -0.6707 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 19.84 | ||||
| Resistance 3 (R3) | 19.77 | 19.10 | 19.53 | ||
| Resistance 2 (R2) | 19.10 | 18.63 | 19.13 | 19.42 | |
| Resistance 1 (R1) | 18.54 | 18.34 | 18.21 | 18.61 | 19.32 |
| Pivot Point | 17.87 | 17.87 | 17.70 | 17.90 | 17.87 |
| Support 1 (S1) | 17.31 | 17.40 | 16.98 | 17.38 | 16.66 |
| Support 2 (S2) | 16.64 | 17.11 | 16.67 | 16.56 | |
| Support 3 (S3) | 16.08 | 16.64 | 16.45 | ||
| Support 4 (S4) | 16.15 |
